These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8923034)

  • 1. Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials.
    Kensler TW; Groopman JD; Wogan GN
    IARC Sci Publ; 1996; (139):237-48. PubMed ID: 8923034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man.
    Kensler TW; Groopman JD; Roebuck BD
    Mutat Res; 1998 Jun; 402(1-2):165-72. PubMed ID: 9675269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
    Kensler TW; Groopman JD
    J Cell Biochem Suppl; 1996; 25():85-91. PubMed ID: 9027603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The uses of carcinogen-DNA adduct measurement in establishing mechanisms of mutagenesis and in chemoprevention.
    Baird WM; Mahadevan B
    Mutat Res; 2004 Mar; 547(1-2):1-4. PubMed ID: 15013693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological relevance of adduct detection to the chemoprevention of cancer.
    Sharma RA; Farmer PB
    Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic considerations in the evaluation of chemopreventive data.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC
    IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of carcinogen dose in chemoprevention studies: quantitative interrelationships between, dibenzo[a,l]pyrene dose, chlorophyllin dose, target organ DNA adduct biomarkers and final tumor outcome.
    Pratt MM; Reddy AP; Hendricks JD; Pereira C; Kensler TW; Bailey GS
    Carcinogenesis; 2007 Mar; 28(3):611-24. PubMed ID: 16973675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention.
    De Flora S; Balansky R; Scatolini L; Di Marco C; Gasparini L; Orlando M; Izzotti A
    IARC Sci Publ; 1996; (139):291-301. PubMed ID: 8923039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents.
    Izzotti A; Camoirano A; Cartiglia C; Grubbs CJ; Lubet RA; Kelloff GJ; De Flora S
    Cancer Res; 1999 Sep; 59(17):4285-90. PubMed ID: 10485473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chemopreventive agents on DNA adduction induced by the potent mammary carcinogen dibenzo[a,l]pyrene in the human breast cells MCF-7.
    Smith WA; Freeman JW; Gupta RC
    Mutat Res; 2001 Sep; 480-481():97-108. PubMed ID: 11506803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinogen biomarkers for lung or oral cancer chemoprevention trials.
    Hecht SS
    IARC Sci Publ; 2001; 154():245-55. PubMed ID: 11220664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts.
    Gyorffy E; Anna L; Kovács K; Rudnai P; Schoket B
    Mutagenesis; 2008 Jan; 23(1):1-18. PubMed ID: 17989146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of carcinogen-DNA adducts and chronic degenerative diseases.
    Izzotti A; D'Agostini F; Bagnasco M; Scatolini L; Rovida A; Balansky RM; Cesarone CF; De Flora S
    Cancer Res; 1994 Apr; 54(7 Suppl):1994s-1998s. PubMed ID: 8137327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiology of lung cancer and the modulation of markers of chronic carcinogen exposure by chemopreventive agents.
    Perera FP; Tang D; Grinberg-Funes RA; Blackwood MA; Dickey C; Blaner W; Santella RM
    J Cell Biochem Suppl; 1993; 17F():119-28. PubMed ID: 8412183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.
    Wogan GN
    Environ Health Perspect; 1992 Nov; 98():167-78. PubMed ID: 1486846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage as an intermediate biomarker in intervention studies.
    Santella RM
    Proc Soc Exp Biol Med; 1997 Nov; 216(2):166-71. PubMed ID: 9349685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinogen-DNA and carcinogen-protein adducts in molecular epidemiology.
    Wild CP; Pisani P
    IARC Sci Publ; 1997; (142):143-58. PubMed ID: 9354917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs.
    Balansky R; Izzotti A; Scatolini L; D'Agostini F; De Flora S
    Cancer Res; 1996 Apr; 56(7):1642-7. PubMed ID: 8603414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.